目的：探讨紫杉醇联合表柔比星新辅助化疗方案治疗三阴性乳腺癌的临床疗效。方法：选取2012年2月-2013年10月笔者所在医院收治的50例三阴性乳腺癌患者为研究对象，将其随机分为对照组和治疗组，各25例。对照组患者采取单纯表柔比星辅助化疗方案，治疗组行紫杉醇联合表柔比星新辅助化疗方案，对两组患者治疗效果、不良反应等进行比较。结果：治疗组患者完全缓解8例(32%)，部分缓解12例(48%)，近期总有效率为80%；对照组患者完全缓解4例(16%)，部分缓解10例(40%)，近期总有效率为56%。两组近期总有效率比较，差异有统计学意义(P<0.05)。结论：紫杉醇联合表柔比星新辅助化疗方案治疗三阴性乳腺癌疗效良好，值得进一步研究应用。%Objective:To investigate the clinical efficacy of Paclitaxel combined with Epirubicin neoadjuvant chemotherapy in the treatment of triple-negative breast cancer.Method:Our hospital from February 2012 to October 2013 were treated 50 cases of triple-negative breast cancer patients for the study, they were divided into the control group(n=25) and the treatment group(n=25),the control group was given the pure Epirubicin adjuvant chemotherapy,the treatment group was given Paclitaxel combined with Epirubicin neoadjuvant chemotherapy,the treatment effect and adverse reactions of two groups were compared.Result:The treatment group,complete remission in 8 cases(32%),partial remission in 12 case(48%),the recent total effective rate was 80%.The control group,complete remission in 4 cases(16%),partial remission in 10 case(40%),the recent total effective rate was 56%,the difference was statistically significant(P<0.05).Conclusion:Paclitaxel combined with Epirubicin neoadjuvant chemotherapy in the treatment of triple-negative breast cancer has a good efficacy,is worthy of further research applications.
展开▼
